PRISTIQ Drug Patent Profile
✉ Email this page to a colleague
When do Pristiq patents expire, and when can generic versions of Pristiq launch?
Pristiq is a drug marketed by Pf Prism Cv and is included in one NDA. There is one patent protecting this drug and two Paragraph IV challenges.
This drug has twenty-two patent family members in sixteen countries.
The generic ingredient in PRISTIQ is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Pristiq
A generic version of PRISTIQ was approved as desvenlafaxine succinate by ALEMBIC on June 29th, 2015.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PRISTIQ?
- What are the global sales for PRISTIQ?
- What is Average Wholesale Price for PRISTIQ?
Summary for PRISTIQ
| International Patents: | 22 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 53 |
| Clinical Trials: | 23 |
| Patent Applications: | 50 |
| Drug Prices: | Drug price information for PRISTIQ |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for PRISTIQ |
| What excipients (inactive ingredients) are in PRISTIQ? | PRISTIQ excipients list |
| DailyMed Link: | PRISTIQ at DailyMed |
Paragraph IV (Patent) Challenges for PRISTIQ
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| PRISTIQ | Extended-release Tablets | desvenlafaxine succinate | 25 mg | 021992 | 1 | 2015-05-08 |
| PRISTIQ | Extended-release Tablets | desvenlafaxine succinate | 50 mg and 100 mg | 021992 | 12 | 2012-02-29 |
US Patents and Regulatory Information for PRISTIQ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-003 | Aug 20, 2014 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-001 | Feb 29, 2008 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-002 | Feb 29, 2008 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for PRISTIQ
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-002 | Feb 29, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-003 | Aug 20, 2014 | ⤷ Sign Up | ⤷ Sign Up |
| Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-002 | Feb 29, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-001 | Feb 29, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-001 | Feb 29, 2008 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for PRISTIQ
See the table below for patents covering PRISTIQ around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
